ARCT - If You Invested $10000 in Arcturus in January This Is How Much You'd Have Now
This might be the year for mRNA drugs. The most prominent name in this space, Moderna , is up a fantastic 700% in 2020. And returns for BioNTech haven't been too shabby with its stock quadrupling in a year. While those investors certainly aren't complaining, the biggest mRNA winner is actually tiny Arcturus Therapeutics (NASDAQ: ARCT) -- $10,000 could have bought you 1,000 shares of Arcturus on Jan. 2. That position would be worth a cool $105,000 as of this writing.
Why is the market in love with these mRNA pharmaceutical stocks? The race to find a COVID-19 vaccine gives us an answer. What people call "the Pfizer drug" is actually the BioNTech drug, as it was the smaller biotech that actually found the molecule . The two front runners in the vaccine race right now are both mRNA drugs.
Image source: Getty Images
For further details see:
If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now